Solanki Sohan Lal, Agarwal Vandana, Ambulkar Reshma P, Joshi Malini P, Chawathey Shreyas, Rudrappa Shivacharan Patel, Bhandare Manish, Saklani Avanish P
Department of Anesthesiology, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Department of Anesthesiology, Critical Care and Pain, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India.
Crit Care Res Pract. 2024 Dec 27;2024:8815211. doi: 10.1155/ccrp/8815211. eCollection 2024.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has become standard treatment for peritoneal cancers and metastases, significantly enhancing survival rates. This study evaluated the relationship between tumor burden, hemodynamic management, and postoperative outcomes after CRS-HIPEC. This study included 203 patients undergoing CRS-HIPEC. The study was registered with ClinicalTrials.gov (NCT02754115). Routine and advanced hemodynamic monitoring was performed. Data on fluid and blood transfusions, coagulation management, body temperature, blood gases, Peritoneal Carcinomatosis Index (PCI), and chemotherapeutic agents used were collected. Postoperatively, complications using the Clavien-Dindo classification were employed. Primary outcomes assessed PCI's impact on hemodynamic parameters and fluid management, with secondary outcomes including postoperative complications, mortality, and length of ICU and hospital stays. Patients with PCI > 20 experienced significantly longer surgeries (796.2 ± 158.3 min) as compared with patients with PCI 0-10 (551 ± 127 min) and patients with PCI between 11 and 20 (661.78 ± 137.7 min) ( ≤ 0.01). Patients with PCI > 20 received higher fluid requirements (mean: 5497.7 ± 2401.9 mL) as compared with PCI 0-10 (2631.2 ± 1459.9 mL) and PCI 10-20 (3964.65 ± 2044.6 mL) ( ≤ 0.01). Patients with PCI > 20 also had a prolonged ICU stays (median: 4 days) as compared with PCI 0-20 (median: 3 days). However, these differences were not significant in patients with PCI between 10 and 20. Significant differences in CI and SVI were observed among PCI groups during and after HIPEC. Significant differences were also observed among PCI groups for postoperative complications. Although 30-day survival rates varied clinically, they did not reach statistical significance. A higher PCI score was significantly associated with increased duration of surgery, fluid requirements, the need for invasive hemodynamic monitoring, postoperative complications, and longer ICU stays. Tailoring perioperative strategies based on PCI scores has the potential to optimize these outcomes. ClinicalTrials.gov identifier: NCT02754115.
细胞减灭术联合腹腔热灌注化疗(CRS-HIPEC)已成为腹膜癌和转移癌的标准治疗方法,显著提高了生存率。本研究评估了CRS-HIPEC术后肿瘤负荷、血流动力学管理与术后结局之间的关系。本研究纳入了203例行CRS-HIPEC的患者。该研究已在ClinicalTrials.gov(NCT02754115)注册。进行了常规和高级血流动力学监测。收集了关于液体和输血、凝血管理、体温、血气、腹膜癌指数(PCI)以及所用化疗药物的数据。术后,采用Clavien-Dindo分类法评估并发症。主要结局评估PCI对血流动力学参数和液体管理的影响,次要结局包括术后并发症、死亡率以及重症监护病房(ICU)和住院时间。与PCI为0 - 10的患者(551±127分钟)和PCI在11至20之间的患者(661.78±137.7分钟)相比,PCI>20的患者手术时间显著更长(796.2±158.3分钟)(P≤0.01)。与PCI为0 - 10的患者(2631.2±1459.9毫升)和PCI为10 - 20的患者(3964.65±2044.6毫升)相比,PCI>20的患者液体需求量更高(平均:5497.7±2401.9毫升)(P≤0.01)。与PCI为0 - 20的患者(中位数:3天)相比,PCI>20的患者ICU住院时间也更长(中位数:4天)。然而,PCI在10至20之间的患者中这些差异不显著。在HIPEC期间及之后,PCI组之间的心脏指数(CI)和每搏量变异指数(SVI)存在显著差异。PCI组之间术后并发症也存在显著差异。尽管30天生存率在临床上有所不同,但未达到统计学显著性。较高的PCI评分与手术时间延长、液体需求量增加、有创血流动力学监测需求、术后并发症以及更长的ICU住院时间显著相关。根据PCI评分调整围手术期策略有可能优化这些结局。ClinicalTrials.gov标识符:NCT02754115。